Strong phase III results in SHTG and expanding REDEMPLO launch drove revenue growth, with net loss widening due to increased R&D and SG&A. Priority review voucher acquisition aims to accelerate SHTG approval, while commercial and pipeline progress positions for future growth.Based on Arrowhead Phar…
Strong phase III results in SHTG and expanding REDEMPLO launch drove revenue growth, with net loss widening due to increased R&D and SG&A. Priority review voucher acquisition aims to accelerate SHTG approval, while commercial and pipeline progress positions for future growth.
Based on
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.